Interview: António Portela, CEO, Bial Portugal
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
Founded in 1924, BIAL is today the biggest Portuguese pharmaceutical group with a team of about 900 collaborators, and with a strong commitment to R&D, internationalization and quality.
BIAL is also an international pharmaceutical group with business activities in more than 50 countries. Based in Portugal, Bial owns facilities in Spain—where a production unit and a R&D centre dedicated to allergic immunotherapy are situated—Italy, Mozambique, Panama, and other countries.
Strongly committed to therapeutic innovation, investing more than 20 percent of its turnover in R&D every year, BIAL Group has launched the first drug of Portuguese patent, an anti-epileptic. Available since 2009 in several European markets, under the brand Zebinix, this antiepileptic, eslicarbazepine acetate, has recently been approved by the regulator of the pharmaceutical market in the US, Food and Drug Administration (FDA), for commercialization in the United States under the brand Aptiom.
BIAL has also a second pharmaceutical for its own research, for the treatment of the Parkinson disease, which is already in an advanced development process (phase III of clinical development).
The company expects to introduce more new medicines and vaccines to the market in the next years, specifically in the central nervous system, the cardiovascular system and allergen immunotherapy, which will be an added impetus to its international expansion.
Since 2005 the Bial Group is a member of the “European Federation of Pharmaceutical Industries and Associations” (EFPIA), which has recognized Bial as a research and development pharmaceutical company capable of bringing new medicines to the world to improve human health and the quality of life of the populations.
Bial Group has also been distinguished by its support to several medical and scientific activities, namely through BIAL Foundation, having as outstanding events the BIAL Award and Scientific Research Grants, well recognized worldwide.
Bial Contact Info:
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado – Portugal
Phone: +351 22986 6100 | Fax: +351 22986 6190
www.bial.com | info@bial.com
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
Ramón Palou de Comasema, Country Director of Amgen Portugal, talks about the struggle to enter the reimbursement process in Portugal, how Amgen Portugal has broken this trend by having three…
David Setboun, Country President of AstraZeneca, discusses the opportunities that the Portuguese market can bring despite economic downturn, and the future of the Portuguese affiliate in expanding to new therapeutic…
Angelini Portugal’s Luigi Cianci offers his critique of the decline of Portugal’s economy and its effects on the industry, talking specifically about the company’s presence in Portugal and its export…
Nelson Ambrogio, managing director of Bayer Portugal, talks about tthe collaboration between the industry and the government, he recent successes of his affiliate, and strategies for continued growth during the…
Servier Portugal’s general manager José Albino Mendes discusses how Portugal’s economic crisis provides real opportunities for growth, the potential for attracting talent in innovative research, and the affiliate’s recently opened…
Nuno Brás, General Manager of LEO Farmacêuticos discusses the effect of the crisis on the Portuguese pharmaceutical market, how being a small privately owned company was an advantage during the…
Fermin Rivas Lopez, Country Manager of Celgene Portugal, gives his insight on Portugal’s recent economic problems, the challenges Celgene Portugal faces due to the economic state of the country, and…
Robin Turner, General Manager of Roche Portugal, looks back on the evolution of the affiliate, and describes how the company managed to recover its debt owed by Portuguese hospitals through…
António Leão, General Manager of Lilly, Portugal, talks about adapting to a challenging economic environment, as well as the importance of the company’s portfolio and pipeline, in Portugal today. Why…
Eduardo Pinto Leite, Director General of GSK Portugal, talks about the recent Portugal bailout, how its effects pushed GSK to some tough decision, and why he sees a brighter future…
See our Cookie Privacy Policy Here
